TABLE A1.
Co-occurring Genomic Alterations With IDH1/2 Mutation Status
Co-Occurring Mutation | IDH1+ iCCA | IDH1– iCCA | IDH2+ iCCA | IDH2– iCCA |
---|---|---|---|---|
Total cases, No. | 426 | 2,641 | 125 | 2,942 |
TP53, % | 12 | 38 | 9 | 35 |
CDKN2A, % | 20 | 32 | 12 | 31 |
CDKN2B, % | 16 | 23 | 9 | 22 |
KRAS (non-G12C), % | 6 | 21 | 2 | 20 |
MTAP, % | 8 | 16 | 6 | 15 |
BAP1, % | 17 | 13 | 23 | 14 |
TERT, % | 0.2 | 8 | 2 | 7 |
SMAD4, % | 1 | 8 | 1 | 8 |
MYC, % | 1 | 5 | 0 | 5 |
FGFR2 fusions, % | 1 | 10 | 1 | 9 |
ERBB2, % | 2 | 5 | 2 | 5 |
BRAF, % | 4 | 5 | 2 | 5 |
PIK3CA, % | 8 | 6 | 3 | 7 |
PTEN, % | 1 | 3 | 2 | 3 |
KRAS G12C, % | 0.20 | 1 | 0 | 1 |
ARID1A, % | 25 | 18 | 19 | 19 |
PBRM1, % | 19 | 10 | 14 | 11 |
STK11, % | 0.2 | 3 | 1 | 3 |
MDM2, % | 1 | 5 | 2 | 4 |
CD274 amplification, % | 0 | 0.30 | 1 | 0.20 |
Abbreviation: iCCA, intrahepatic cholangiocarcinoma.